NCT02143856

Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food

A Randomized, Open-label, Two-way Cross-over Study to Determine the Oral Bioavailability of GLPG1205 After Single-dose Intake in Healthy Male Subjects as a Solid Formulation, With and Without Food

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Galapagos NV · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to evaluate the amount of compound present in the blood (relative bioavailability) after a single oral administration of GLPG1205 given as a capsule formulation in fasted versus fed conditions in male healthy subjects. Also, the safety and tolerability of a single oral dose of GLPG1205 given as a capsule formulation under fasted and fed conditions will be assessed.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	100 mg GLPG1205	A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg

Timeline

• Start date: 2014-05-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2014-05-21
• Last updated: 2014-07-22

Locations

1 site across 1 country: Belgium